Summary
The episode works through the difference between a substance's schedule and a product's market authorization, using a hypothetical ketamine-assisted psychotherapy clinic in Edmonton to show which federal and Alberta authorizations apply to ketamine and to psilocybin. Sarah and Kiffer then examine what the Controlled Substances Regulations changed on 1 October 2026, what the Toth and Lance decisions required of the Minister, and why two published counts of Special Access Program approvals cannot be subtracted from each other. A weighted comparison of Australia's and Oregon's access models, using ratings invented for the exercise, shows how a change in one weight reverses the ranking, and the rule of three shows that a July 2026 report of no adverse events among 188 patients in Australia's scheme is consistent with a true rate as high as about 1.6 percent. The hosts debate whether British Columbia should adopt Alberta's psychiatrist-led licensing model and close with general legal information on what a counsellor may do when a client plans to use psilocybin outside an authorized route, with a pointer to legal advice and college guidance.